Generic Threat Puts Biologic Firms On The Defensive (Investor's Business Daily via Yahoo! News)
Technology marches on, but the law and regulations often don't keep up. That's been the case with biological drugs, which are made from proteins instead of chemicals.

Avastin adds non-small cell lung cancer to list of FDA approvals (Cancerfacts.com)
SAN FRANCISCO Oct. 11, 2006 Genentech, Inc. (NYSE: DNA) announced today that the FDA has approved Avastin (bevacizumab) to be used in combination with chemotherapy for treatment of certain types of non-small cell lung cancer.